Philadelphia has earned the nickname “Cellicon Valley,” and the numbers back it up: the city hosts roughly 60 of the world’s 500 cell-and-gene therapy companies, a concentration unmatched outside of Boston and the Bay Area.
The big bets
- Johnson & Johnson is building a $1 billion cell therapy manufacturing facility in Montgomery County, with construction starting in late 2026 and production beginning in 2031.
- Alveus Therapeutics raised a $160 million Series A.
- Century Therapeutics closed a $135 million round.
- Children’s Hospital of Philadelphia won $39 million in federal funding for rare pediatric disease research platforms.
State backing behind the boom
Governor Josh Shapiro’s 2026-27 state budget includes $125 million to launch Innovate in PA 2.0, a program funding promising Pennsylvania startups. Shapiro announced the initiative at B+labs, a life-sciences incubator in Philadelphia’s Schuylkill Yards offering wet and dry chemistry labs and shared research equipment. Pennsylvania’s broader startup ecosystem tracks 152 funded companies across 52 cities, with Philadelphia and Pittsburgh anchoring the majority of activity — but it’s the cell-and-gene therapy cluster that gives the state its clearest national identity in healthcare.
